Bisphosphonate use in conditions other than osteoporosis

Annals of the New York Academy of Sciences

Volumn 1218, Issue 1, 2011, Pages 33-37

  Silverman, Stuart L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bisphosphonates; Osteogenesis imperfecta; Osteonecrosis of the hip; Paget's disease; Peridontitis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID; GLUCOCORTICOID; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; TILUDRONIC ACID; ZOLEDRONIC ACID;

ARTICLE; BONE DENSITY; BONE MASS; BONE NECROSIS; BONE PAIN; BONE REMODELING; BONE TURNOVER; CALCINOSIS; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DERMATOMYOSITIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG APPROVAL; DRUG EFFICACY; FIBROUS DYSPLASIA; HUMAN; IMPLANT; NONHUMAN; OSTEOGENESIS IMPERFECTA; OSTEOPOROSIS; PAGET BONE DISEASE; PERIODONTAL DISEASE; PERIODONTITIS; PERIPROSTHETIC FRACTURE; POSTMENOPAUSE OSTEOPOROSIS; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; TOOTH IMPLANTATION; TOTAL KNEE REPLACEMENT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 79551569541     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05769.x     Document Type: Article

References (38)

1. Siris, E.S. & G.D. Roodman 2003. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 5th ed. M.J. Favus, Ed.: 495-506. ASMBR. Washington, DC.
2. Altman, R.D., D.A. Bloch, M.C. Hochberg, et al 2000. Prevalence of pelvic Paget's disease of bone in the United States. J. Bone Miner. Res. 15: 461-465.
3. United States Census Bureau. 2007. American Fact Finder. Available at: Accessed April 13.
4. Roodman, G.D. & J.J. Windle 2005. Paget's disease of bone. J. Clin. Invest. 115: 200-208.
5. Lyles, K.W., E.S. Siris, F.R. Singer, et al 2001. A clinical approach to diagnosis and management of Paget's disease of bone. J. Bone Miner. Res. 16: 1379-1387.
6. Selby, P.L., M.W. Davie, S.H. Ralston, et al 2002. Guidelines on the management of Paget's disease of bone. Bone 31: 366-373.
7. Langston, A.L. & S.H. Ralston 2004. Management of Paget's disease of bone. Rheumatology (Oxford) 43: 955-959. Epub 2004 Jun 8.
8. Package insert of each product.
9. Reid, I.R., P. Miller, K. Lyles, et al 2005. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N. Engl. J. Med. 353: 898-908.
10. Hosking, D., K. Lyles, J.P. Brown, et al 2007. Long term control of bone turnover in Paget's disease with zoledronic acid and risedronate. J. Bone Miner. Res. 22: 142-148.
11. Rauch, F. & F.H. Glorieux 2004. Osteogenesis imperfecta. Lancet 363: 1377-1385.
12. Rauch, F. & F.H. Glorieux 2006. Treatment of children with osteogenesis imperfecta. Curr. Osteoporos. Rep. 4: 159-164.
13. Glorieux, F.H., N.J. Bishop, H. Plotkin, et al 1998. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N. Engl. J. Med. 339: 947-952.
14. Rauch, F., H. Plotkin, L. Zeitlin & F.H. Glorieux 2003. Bone mass, size and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy. JBMR 18: 610-614.
15. Munns, C.F., F. Rauch, R. Travers, et al Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: clinical and histomorphometric outcome. J. Bone Miner. Res. 2005; 20: 1235-1243. Epub 2005 Feb 21.
16. Salehpour, S. & S. Tavakkoli Cyclic pamidronate therapy in children with osteogenesis imperfect. J. Pediatr. Endocrinol. Metab. 2010; 23: 73-80.
17. Glorieux, F.H., N.J. Bishop, H. Plotkin, et al 1998. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N. Engl. J. Med.339: 947-952.
18. Zeitlin, L., F. Rauch, H. Plotkin, et al 2003. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III and IV. Pediatrics 111(5 Pt 1): 1030-1036.
19. Land, C., F. Rauch, K. Montpetit, et al 2006. Effect of intravenous pamidronate therapy on functional abilities and level of ambulation in children with osteogenesis imperfecta. J. Pediatr. 148: 456-460.
20. Rauch, F., S. Cornibert, M. Cheung, et al Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta. Bone 2007; 40: 821-827. Epub 2007 Jan 12.
21. Jablorski, M., M. Gorczlak, K. Turzanska 2006. Rationale for bisphosphonate use in patients with endoprosthesis. Ortop. Truamatol. Rehab. 8: 226-231.
22. Soininvaara, T.A., J.S. Jurvelin, H.J. Miettinen, et al 2002. Effect of alendronate on periprosthetic bone loss after total knee arthroplasty: a one-year, randomized, controlled trial of 19 patients. Calcif. Tissue Int. 71: 472-477. Epub 2002 Oct 10.
23. Wilkinson, J.M., A.J. Hamer, I. Stockley, et al 2005. Polyethylene wear rate and osteolysis threshold versus continuous dose-response relationship. J. Orthop. Res. 23: 520-525. Epub 2005 Jan 19.
24. Kurth, A.H., C. Eberhardt, S. Muller, et al 2005. The bisphosphonate ibandronate improves implant integration in osteopenic ovariectomized rats. Bone 37: 204-210.
25. Peter, B., D.P. Pioletti, S. Laib, et al 2005. Calcium phosphate drug delivery system: influence of local zoledronate release on bone implant osteointegration. Bone 36: 52-60. Epub 2004 Nov 23.
26. Bobyn, J.D., M. Tanzer, D. Karabasz, et al 2005. The Otto Aufranc Award: bone augmentation around and within porous implants by local bisphosphonate elution. Clin. Orthop. Relat. Res. 441: 30-39.
27. Jeffcoat, M.K. 2006. Safety of oral bisphosphonates: controlled studies on alveolar bone. J. Oral Maxillofac. Implants 21: 349-353.
28. Reddy, M.S., T.W. Weatherford 3rd, C.A. Smith, et al 1995. Alendronate treatment of naturally occurring peridontitis in beagle dogs. J. Peridontol. 66: 211-217.
29. Little, D.G., R.A. Peat, A. McEvoy, et al 2003. Zoledronic acid treatment results in retention of femoral head structure after traumatic osteonecrosis in young Wistar rats. J. Bone Miner. Res. 18: 2016-2022.
30. Little, D.G., M. McDonald, I.T. Sharpe, et al 2005. Zoledronic acid improves femoral head sphericity in a rat model of perthes disease. J. Orthop. Res. 23: 862-868.
31. Kim, H.K., T.S. Randall, H. Bian, et al 2005. Ibandronate for prevention of femoral head deformity after ischemic necrosis of the capital femoral epiphysis in immature pigs. J. Bone Joint Surg. Am. 87: 550-557.
32. Astrand, J. & P. Aspenberg 2002. Systemic alendronate prevents resorption of necrotic bone during revascularization. A bone chamber study in rats. BMC Musculoskelet. Disord. 3: 19.
33. Agarwala, S., D. Jain, V.R. Joshi, et al 2005. Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label study. Rheumatology (Oxford) 44: 352-359. Epub 2004 Nov 30. Erratum in: Rheumatology (Oxford) 2005; 44 569.
34. Lai, K.A., W.J. Shen, C.Y. Yang, et al 2005. The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study. J. Bone Joint Surg. Am. 87: 2155-2159.
35. DiMeglio, L.A. 2007. Bisphosphonate therapy for fibrous dysplasia. Pediatr. Endocrinol. Rev. 4 Suppl 4: 440-445.
36. Leet, A.I. & M.T. Collins 2007. Current approach to fibrous dysplasia of bone and McCune-Albright syndrome. J. Child Orthop. 1: 3-17. Epub 2007 Feb 23.
37. Chao, K. & L. Katznelson 2008. Use of high-dose oral bisphosphonate therapy for symptomatic fibrous dysplasia of the skull. J. Neurosurg. 109: 889-892.
38. Marco Puche, A., Calvo Penades, I, Lopez Montesinos, B. 2010. Effectiveness of the treatment with intravenous pamidronate in calcinosis in juvenile dermatomyositis. Clin. Exp. Rheumatol. 28: 135-140.